China Bio-B (02509) released unaudited interim results for the six months ended June 30, 2024, with revenue of CNY 44.919 million and no revenue in the same period last year; gross profit of CNY 37.756 million; and research and development expenses of CNY 0.145 billion.
The announcement stated that the revenue came from authorization fees and R&D service fees for QX008N and QX004N authorized transactions, reflecting the group's strong R&D capabilities.